A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants

Study identifier:D6402C00014

ClinicalTrials.gov identifier:NCT06651021

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of a Single Dose of Balcinrenone/Dapagliflozin in Healthy Chinese Participants

Medical condition

Healthy Volunteer

Phase

Phase 1

Healthy volunteers

Yes

Study drug

balcinrenone/dapagliflozin

Sex

All

Actual Enrollment

10

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 21 Oct 2024
Primary Completion Date: 28 Oct 2024
Study Completion Date: 28 Oct 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria